P2RY12 and chronic kidney disease: Additionally, we also tested for possible confounding effects of cardiovascular risk factors (diabetes type 2, smoking status, arterial hypertension, and hyperlipidemia), comedication (P2Y12 [purinergic receptor type Y, subtype 12 inhibitors]), and comorbidities (heart failure defined by New York Heart Association class, symptomatic coronary artery disease, chronic kidney disease, and atrial fibrillation) on the progression rate of AS using PLS-DA and OPLS-DA analysis depicted in Figure S11.